Wells Fargo
RARE icon

Wells Fargo’s Ultragenyx Pharmaceutical RARE Stock Holding History

Wells Fargo’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-200
Closed -$15K – 7350
2022
Q1 		$15K Hold
200
– – ﹤0.01% 6130
2021
Q4 		$17K Buy
+200
New +$16.3K ﹤0.01% 6382
2019
Q3 		– Sell
-76,500
Closed -$124K – 6641
2019
Q2 		$124K Buy
+76,500
New +$4.87M ﹤0.01% 5213

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wells Fargo's RARE Position: Q1 2026 in Review

Wells Fargo increased its Ultragenyx Pharmaceutical (RARE) stake by 8.2% in Q1 2026, buying an estimated $117K and bringing the position to 68,765 shares worth $1.44M. The position accounts for ﹤0.01% of the portfolio, ranked #3517.

Wells Fargo first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $199M in Q4 2015. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Wells Fargo held 68,765 shares of Ultragenyx Pharmaceutical worth $1.44M as of Q1 2026.
  • Wells Fargo bought 5,202 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $117K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3517 holding.
  • Wells Fargo first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • Wells Fargo's Ultragenyx Pharmaceutical position peaked at $199M in Q4 2015.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.